Intellia Therapeutics, Inc. (NASDAQ:NTLA) Given Average Recommendation of “Moderate Buy” by Brokerages

Intellia Therapeutics, Inc. (NASDAQ:NTLA) has been given an average rating of “Moderate Buy” by the twenty-one ratings firms that are covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the company. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $34.95.

A number of research analysts have issued reports on the company. Truist Financial decreased their price target on Intellia Therapeutics from $90.00 to $50.00 and set a “buy” rating for the company in a report on Tuesday, March 4th. Canaccord Genuity Group reduced their target price on Intellia Therapeutics from $74.00 to $54.00 and set a “buy” rating for the company in a research note on Tuesday. Wolfe Research raised Intellia Therapeutics from a “peer perform” rating to an “outperform” rating and set a $21.00 target price for the company in a research note on Monday, April 21st. Wedbush reaffirmed a “neutral” rating and set a $7.00 target price (down from $10.00) on shares of Intellia Therapeutics in a research note on Thursday, May 29th. Finally, Guggenheim reduced their target price on Intellia Therapeutics from $55.00 to $45.00 and set a “buy” rating for the company in a research note on Monday, May 12th.

Intellia Therapeutics Trading Up 7.4%

Shares of NASDAQ:NTLA opened at $7.69 on Wednesday. Intellia Therapeutics has a 12-month low of $5.90 and a 12-month high of $28.18. The company has a market capitalization of $796.55 million, a PE ratio of -1.41 and a beta of 2.33. The business has a 50 day moving average of $7.90 and a two-hundred day moving average of $10.17.

Intellia Therapeutics (NASDAQ:NTLA) last announced its quarterly earnings results on Thursday, May 8th. The company reported ($1.10) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.26) by $0.16. The company had revenue of $16.63 million during the quarter, compared to analyst estimates of $11.39 million. During the same period in the previous year, the firm posted ($1.12) earnings per share. The company’s revenue was down 42.6% compared to the same quarter last year. Equities research analysts predict that Intellia Therapeutics will post -5.07 earnings per share for the current fiscal year.

Institutional Trading of Intellia Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in shares of Intellia Therapeutics by 8.0% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 521,706 shares of the company’s stock worth $3,709,000 after acquiring an additional 38,521 shares during the last quarter. Woodline Partners LP acquired a new stake in shares of Intellia Therapeutics in the 1st quarter worth $171,000. Arete Wealth Advisors LLC increased its stake in shares of Intellia Therapeutics by 21.8% in the 1st quarter. Arete Wealth Advisors LLC now owns 12,512 shares of the company’s stock worth $89,000 after acquiring an additional 2,240 shares during the last quarter. Granahan Investment Management LLC increased its stake in shares of Intellia Therapeutics by 55.3% in the 1st quarter. Granahan Investment Management LLC now owns 475,946 shares of the company’s stock worth $3,384,000 after acquiring an additional 169,436 shares during the last quarter. Finally, AQR Capital Management LLC increased its stake in shares of Intellia Therapeutics by 154.1% in the 1st quarter. AQR Capital Management LLC now owns 90,875 shares of the company’s stock worth $646,000 after acquiring an additional 55,118 shares during the last quarter. 88.77% of the stock is owned by institutional investors and hedge funds.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.